Meeting
2024 ASCO Annual Meeting
Neurofilament light chains: A biomarker for vincristine-related neuropathy.
Authors
Gretchen A McNally
The Ohio State University James Cancer Center, Columbus, OH
Gretchen A McNally , Menglin Xu , Timothy Voorhees , Robert A. Baiocchi , David Alan Bond , Naren Epperla , Kami J. Maddocks , Yazeed Sawhala , Bhuvaneswari Ramaswamy , Maryam B. Lustberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptom Science and Palliative Care
Track
Symptom Science and Palliative Care
Sub Track
Toxicities–Prevention and Management Strategies
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 12114)
DOI
10.1200/JCO.2024.42.16_suppl.12114
Abstract #
12114
Poster Bd #
243
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
First Author: Mariano Provencio-Pulla
Poster
2023 ASCO Annual Meeting
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
First Author: Lorenzo Falchi
Poster
2023 ASCO Annual Meeting
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
First Author: Luciana Vinti
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin